# DESCRIPTION

## FIELD OF THE INVENTION

- define invention scope

## BACKGROUND OF THE INVENTION

- motivate muscular dystrophy treatment

## SUMMARY OF THE INVENTION

- provide method for treating muscular dystrophy
- administer small molecule compound orally or parenterally
- specify small molecule compounds
- provide method for treating muscular dystrophy with compound of formula (I)
- specify muscular dystrophy types
- provide method for reducing symptoms of muscular dystrophy
- administer small molecule compound orally or parenterally
- specify small molecule compounds
- provide method for reducing symptoms of muscular dystrophy with compound of formula (I)
- specify muscular dystrophy types
- provide method for increasing utrophin promoter activity
- administer small molecule compound orally or parenterally
- specify small molecule compounds
- provide method for increasing utrophin promoter activity with compound of formula (I)
- provide method for increasing utrophin expression or activity
- provide method for correcting dystrophin deficiency
- provide method for treating muscular dystrophy
- specify small molecule compound administration
- specify compound of formula (I) administration
- specify muscular dystrophy types
- provide method for reducing symptoms of muscular dystrophy
- specify small molecule compound administration
- specify compound of formula (I) administration
- specify muscular dystrophy types
- provide method for increasing utrophin promoter activity
- specify small molecule compound administration
- specify compound of formula (I) administration
- specify muscular dystrophy types
- provide method for increasing utrophin expression or activity
- specify small molecule compound administration
- specify compound of formula (I) administration
- specify muscular dystrophy types
- provide method for correcting dystrophin deficiency
- specify small molecule compound administration
- specify compound of formula (I) administration

## DEFINITIONS

- define substituted compounds
- explain stable compounds
- define aliphatic groups
- describe alkyl, alkenyl, and alkynyl groups
- define alicyclic groups
- explain cycloalkyl groups
- define heteroaliphatic groups
- describe heteroalicyclic and heterocyclic groups
- explain substituted heterocycloalkyl or heterocycle groups
- define aromatic moieties
- describe heteroaromatic moieties
- explain attachment of aromatic and heteroaromatic moieties
- define aryl groups
- define heteroaryl
- define aryl and heteroaryl groups
- define alkoxy
- define thioalkyl
- define alkylamino and aminoalkyl
- list examples of substituents
- define halo and halogen
- define haloalkyl, amino, and acyl
- define C2-6alkenylene and other terms

## DETAILED DESCRIPTION OF THE INVENTION

- define muscular dystrophy
- describe small molecule therapy embodiments
- introduce small molecule compound structures
- describe piperine and its analogs
- describe apigenin and its analogs
- describe other small molecule compounds and their analogs
- provide examples of small molecule compounds
- summarize small molecule compound analogs
- describe leflunomide
- list analogs of leflunomide
- describe kawain
- list analogs of kawain
- describe clorgyline
- list analogs of clorgyline
- describe equilin
- list analogs of equilin
- define isomers
- define prodrugs
- define pharmaceutically acceptable salts
- list examples of inorganic salts
- list examples of organic salts
- describe pharmaceutical products
- outline methods for treating muscular dystrophy
- provide method for increasing utrophin promoter activity
- provide method for increasing utrophin expression or activity
- provide method for correcting dystrophin deficiency
- provide method for treating muscular dystrophy
- provide method for reducing muscular dystrophy symptoms
- provide method for increasing utrophin promoter activity with piperine
- provide method for increasing utrophin expression or activity with piperine
- provide method for correcting dystrophin deficiency with piperine
- provide method for treating muscular dystrophy with piperine
- provide method for reducing muscular dystrophy symptoms with piperine
- provide method for increasing utrophin promoter activity with apigenin
- provide method for increasing utrophin expression or activity with apigenin
- provide method for treating muscular dystrophy with apigenin
- provide method for increasing utrophin promoter activity
- provide method for increasing utrophin expression or activity
- provide method for correcting dystrophin deficiency
- provide method for treating muscular dystrophy
- provide method for reducing muscular dystrophy symptoms
- provide method for increasing utrophin promoter activity with apigenin
- provide method for increasing utrophin expression or activity with apigenin
- provide method for correcting dystrophin deficiency with apigenin
- provide method for treating muscular dystrophy with apigenin
- provide method for reducing muscular dystrophy symptoms with apigenin
- provide method for increasing utrophin promoter activity with chrysin
- provide method for increasing utrophin expression or activity with chrysin
- provide method for correcting dystrophin deficiency with chrysin
- provide method for treating muscular dystrophy with chrysin
- provide method for reducing muscular dystrophy symptoms with chrysin
- provide method for increasing utrophin promoter activity with nabumetone
- provide method for increasing utrophin expression or activity with nabumetone
- provide method for treating muscular dystrophy with nabumetone
- provide method for treating muscular dystrophy
- provide method for reducing symptoms of muscular dystrophy
- provide method for increasing utrophin promoter activity
- provide method for increasing utrophin expression or activity
- provide method for correcting dystrophin deficiency
- provide method for treating muscular dystrophy with utrophin promoter activity
- provide method for treating muscular dystrophy with utrophin expression or activity
- provide method for reducing symptoms of muscular dystrophy with utrophin promoter activity
- provide method for reducing symptoms of muscular dystrophy with utrophin expression or activity
- provide method for treating muscular dystrophy with nabumetone
- provide method for reducing symptoms of muscular dystrophy with nabumetone
- provide method for increasing utrophin promoter activity with riluzole
- provide method for increasing utrophin expression or activity with riluzole
- provide method for treating muscular dystrophy with riluzole
- provide method for treating muscular dystrophy
- provide method for reducing symptoms of muscular dystrophy
- increase activity of utrophin promoter
- increase expression or activity of utrophin
- correct deficiency of dystrophin
- treat muscular dystrophy with hesperetin
- reduce symptoms of muscular dystrophy with hesperetin
- increase activity of utrophin promoter with hesperetin
- increase expression or activity of utrophin with hesperetin
- correct deficiency of dystrophin with hesperetin
- treat muscular dystrophy with resveratrol
- reduce symptoms of muscular dystrophy with resveratrol
- increase activity of utrophin promoter with resveratrol
- increase expression or activity of utrophin with resveratrol
- provide method for increasing utrophin promoter activity
- provide method for increasing utrophin expression
- provide method for correcting dystrophin deficiency
- provide method for treating muscular dystrophy
- provide method for reducing muscular dystrophy symptoms
- provide method for increasing utrophin promoter activity with resveratrol
- provide method for increasing utrophin expression with resveratrol
- provide method for correcting dystrophin deficiency with resveratrol
- provide method for treating muscular dystrophy with resveratrol
- provide method for reducing muscular dystrophy symptoms with resveratrol
- provide method for increasing utrophin promoter activity with phenazopyridine
- provide method for increasing utrophin expression with phenazopyridine
- provide method for treating muscular dystrophy with phenazopyridine
- provide method for reducing muscular dystrophy symptoms with phenazopyridine
- provide method for increasing utrophin promoter activity
- provide method for increasing utrophin expression or activity
- provide method for correcting dystrophin deficiency
- provide method for treating muscular dystrophy
- provide method for reducing muscular dystrophy symptoms
- provide method for increasing utrophin promoter activity with tiabendazole
- provide method for increasing utrophin expression or activity with tiabendazole
- provide method for correcting dystrophin deficiency with tiabendazole
- provide method for treating muscular dystrophy with tiabendazole
- provide method for reducing muscular dystrophy symptoms with tiabendazole
- provide method for increasing utrophin promoter activity with leflunomide
- provide method for increasing utrophin expression or activity with leflunomide
- provide method for correcting dystrophin deficiency with leflunomide
- provide method for treating muscular dystrophy with leflunomide
- provide method for reducing muscular dystrophy symptoms with leflunomide
- provide method for treating muscular dystrophy with tiabendazole or leflunomide
- provide method for reducing muscular dystrophy symptoms with tiabendazole or leflunomide
- provide method for treating muscular dystrophy with tiabendazole or leflunomide
- provide method for treating muscular dystrophy
- provide method for reducing symptoms of muscular dystrophy
- provide method for increasing activity of utrophin promoter
- provide method for increasing expression or activity of utrophin
- provide method for correcting deficiency of dystrophin
- provide method for treating muscular dystrophy with kawain
- provide method for reducing symptoms of muscular dystrophy with kawain
- provide method for increasing activity of utrophin promoter with kawain
- provide method for increasing expression or activity of utrophin with kawain
- provide method for correcting deficiency of dystrophin with kawain
- provide method for treating muscular dystrophy with clorgyline
- provide method for reducing symptoms of muscular dystrophy with clorgyline
- provide method for increasing activity of utrophin promoter with clorgyline
- provide method for increasing expression or activity of utrophin with clorgyline
- provide method for treating muscular dystrophy
- provide method for reducing symptoms of muscular dystrophy
- provide method for increasing utrophin promoter activity
- provide method for increasing utrophin expression or activity
- provide method for correcting dystrophin deficiency
- provide method for treating muscular dystrophy with utrophin promoter activity
- provide method for treating muscular dystrophy with utrophin expression or activity
- provide method for reducing symptoms of muscular dystrophy with utrophin promoter activity
- provide method for reducing symptoms of muscular dystrophy with utrophin expression or activity
- provide method for treating muscular dystrophy with equilin
- provide method for reducing symptoms of muscular dystrophy with equilin
- provide method for increasing utrophin promoter activity with equilin
- provide method for increasing utrophin expression or activity with equilin
- provide method for correcting dystrophin deficiency with equilin

### Pharmaceutical Compositions and Methods of Administration

- describe administration methods
- formulate for oral administration
- formulate for intravenous administration
- formulate for topical administration
- formulate for suppository administration
- describe carriers and diluents
- describe liquid formulations
- describe controlled-release compositions
- describe delivery systems
- describe combination therapies

## EXAMPLES

- screen chemical library for utrophin promoter activators
- identify and characterize dose-dependent activators
- evaluate activity of selected compounds in muscle cells and in vivo
- suggest therapeutic utility in muscular dystrophy

